Affimed Analyst Ratings
Affimed Analyst Ratings
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price Affimed (AFMD) is trading at is $0.31, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 1492.36% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 09/25/2023 | 2129.3% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 09/12/2023 | 2129.3% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 09/07/2023 | 2129.3% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 1810.83% | Truist Securities | $8 → $6 | Maintains | Buy |
| 08/11/2023 | 1492.36% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/08/2023 | 1810.83% | Berenberg | → $6 | Assumes | → Buy |
| 06/05/2023 | 1492.36% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 05/24/2023 | 1810.83% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/27/2023 | 2129.3% | Wells Fargo | → $7 | Assumes | → Overweight |
| 03/24/2023 | 218.47% | Stifel | $2 → $1 | Maintains | Hold |
| 03/24/2023 | 1810.83% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 12/12/2022 | 2129.3% | Wells Fargo | $8 → $7 | Maintains | Overweight |
| 12/12/2022 | 1810.83% | Piper Sandler | $7 → $6 | Maintains | Overweight |
| 12/12/2022 | 1810.83% | SVB Leerink | $10 → $6 | Maintains | Outperform |
| 12/12/2022 | 1810.83% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 10/10/2022 | 536.94% | Stifel | $9 → $2 | Downgrades | Buy → Hold |
| 06/23/2022 | 2766.24% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 03/31/2022 | 2129.3% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 3721.66% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 10/21/2021 | 3084.71% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/12/2021 | 3721.66% | SVB Leerink | $13 → $12 | Maintains | Outperform |
| 09/30/2021 | 3721.66% | Stifel | → $12 | Initiates Coverage On | → Buy |
| 03/31/2021 | 4677.07% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 03/24/2021 | 4677.07% | Wells Fargo | $10 → $15 | Maintains | Overweight |
| 03/11/2021 | 4358.6% | SVB Leerink | $9 → $14 | Maintains | Outperform |
| 11/11/2020 | 2766.24% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 06/24/2020 | 2447.77% | SVB Leerink | $7 → $8 | Maintains | Outperform |
| 03/28/2019 | 2447.77% | SVB Leerink | → $8 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/15/2023 | 1492.36% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 09/25/2023 | 2129.3% | 坎托·菲茨杰拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 09/12/2023 | 2129.3% | 坎托·菲茨杰拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 09/07/2023 | 2129.3% | 坎托·菲茨杰拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 08/11/2023 | 1810.83% | Truist 证券 | 8 美元 → 6 美元 | 维护 | 买 |
| 08/11/2023 | 1492.36% | HC Wainwright & Co. | → 5 美元 | 重申 | 购买 → 购买 |
| 08/08/2023 | 1810.83% | 贝伦贝格 | → 6 美元 | 假设 | → 购买 |
| 06/05/2023 | 1492.36% | HC Wainwright & Co. | 6 美元 → 5 美元 | 维护 | 买 |
| 05/24/2023 | 1810.83% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
| 03/27/2023 | 2129.3% | 富国银行 | → 7 美元 | 假设 | → 超重 |
| 2023 年 3 月 24 日 | 218.47% | Stifel | $2 → $1 | 维护 | 保持 |
| 2023 年 3 月 24 日 | 1810.83% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
| 2022 年 12 月 12 日 | 2129.3% | 富国银行 | 8 美元 → 7 美元 | 维护 | 超重 |
| 2022 年 12 月 12 日 | 1810.83% | 派珀·桑德勒 | 7 美元 → 6 美元 | 维护 | 超重 |
| 2022 年 12 月 12 日 | 1810.83% | SVB Leerink | 10 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 2022 年 12 月 12 日 | 1810.83% | HC Wainwright & Co. | → 6 美元 | 启动覆盖范围开启 | → 购买 |
| 2022 年 10 月 10 日 | 536.94% | Stifel | 9 美元 → 2 美元 | 降级 | 买入 → 持有 |
| 06/23/2022 | 2766.24% | SVB Leerink | 10 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 03/31/2022 | 2129.3% | 派珀·桑德勒 | → 7 美元 | 启动覆盖范围开启 | → 超重 |
| 2022 年 2 月 23 日 | 3721.66% | 坎托·菲茨杰拉德 | → 12 美元 | 启动覆盖范围开启 | → 超重 |
| 2021 年 10 月 21 日 | 3084.71% | Truist 证券 | → 10 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 12 月 10 日 | 3721.66% | SVB Leerink | 13 美元 → 12 美元 | 维护 | 跑赢大盘 |
| 09/30/2021 | 3721.66% | Stifel | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 3 月 31 日 | 4677.07% | 瑞士信贷 | → 15 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 3 月 24 日 | 4677.07% | 富国银行 | 10 美元 → 15 美元 | 维护 | 超重 |
| 03/11/2021 | 4358.6% | SVB Leerink | 9 美元 → 14 美元 | 维护 | 跑赢大盘 |
| 11/11/2020 | 2766.24% | SVB Leerink | 8 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 06/24/2020 | 2447.77% | SVB Leerink | 7 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 03/28/2019 | 2447.77% | SVB Leerink | → 8 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Affimed (AFMD)?
Affimed（AFMD）的目标价格是多少？
The latest price target for Affimed (NASDAQ: AFMD) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $5.00 expecting AFMD to rise to within 12 months (a possible 1492.36% upside). 16 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月15日公布了Affimed（纳斯达克股票代码：AFMD）的最新目标股价。该分析公司将目标股价定为5.00美元，预计AFMD将在12个月内升至12个月内（可能上涨1492.36％）。去年有16家分析公司公布了评级。
What is the most recent analyst rating for Affimed (AFMD)?
分析师对 Affimed (AFMD) 的最新评级是多少？
The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by HC Wainwright & Co., and Affimed reiterated their buy rating.
HC Wainwright & Co. 对Affimed（纳斯达克股票代码：AFMD）的最新分析师评级由HC Wainwright & Co. 提供，Affimed重申了买入评级。
When is the next analyst rating going to be posted or updated for Affimed (AFMD)?
Affimed（AFMD）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Affimed的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Affimed的最新评级是在2023年11月15日公布的，因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Affimed (AFMD) correct?
分析师评级申明 (AFMD) 是否正确？
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $5.00. The current price Affimed (AFMD) is trading at is $0.31, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的Affimed（AFMD）评级，目标股价为0.00美元至5.00美元。Affimed（AFMD）目前的交易价格为0.31美元，在分析师的预测区间内。
